Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA May 12, 2026
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop SC Formulations of Multiple Promising Oncology Targets May 12, 2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies May 12, 2026
Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer May 12, 2026
Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform May 12, 2026
CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma May 12, 2026
Kanvas Biosciences Secures $48M Series A to Deliver Novel Microbiome Therapeutics to Cancer Patients May 12, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) May 6, 2026
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 May 6, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel May 6, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera April 28, 2026
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology April 21, 2026
Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas April 21, 2026
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer April 21, 2026
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development April 21, 2026
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement April 21, 2026
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15 April 21, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform April 21, 2026
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Gen Dual-Payload ADCs April 21, 2026
C4 Therapeutics and Roche Enter New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) April 15, 2026
Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
